Dilip Challa
About Dilip Challa
Dilip Challa is a Senior Scientist with expertise in designing and testing protein-based therapeutics and vaccines for cancer and inflammatory diseases. He has over 10 years of research experience in T cell biology, antibody engineering, tumor immunology, and autoimmunity.
Current Role at Alloy Therapeutics
Dilip Challa serves as a Senior Scientist at Alloy Therapeutics, Inc. since 2022. In this role, he focuses on the design and development of protein-based therapeutics and vaccines, particularly targeting cancer and inflammatory diseases. His expertise in T cell biology and antibody engineering contributes to the advancement of innovative therapeutic solutions within the company.
Previous Experience in Research
Prior to his current position, Dilip Challa held several research roles. He worked as a Scientist II at Alloy Therapeutics, Inc. from 2021 to 2022, and as a Research Scientist at the Broad Institute of MIT and Harvard from 2020 to 2021. He also served as a Scientist at AVANTGEN, INC. from 2019 to 2020, and completed a Postdoctoral Researcher position at Texas A&M University from 2016 to 2019.
Education and Expertise
Dilip Challa has a strong educational background in Immunology and Biotechnology. He earned his Doctor of Philosophy (PhD) in Immunology from UT Southwestern Medical Center, where he studied from 2008 to 2016. He also holds a Master of Research (MRes) in Immunology from The University of Manchester, completed in 2008, and a Bachelor of Engineering (BE) in Biotechnology from RV College of Engineering, obtained in 2007.
Research Specialization
Dilip Challa has over 10 years of research experience specializing in T cell biology, antibody engineering, tumor immunology, and autoimmunity. His work includes the use of single-cell platforms for antibody discovery, which enhances the development of targeted therapies. This specialization supports his contributions to the field of immunotherapy and vaccine development.